Skip to main contentSkip to navigation
Sirius Investors

SLRN Stock: Acelyrin, Inc. Stock Price, Analysis & Insights

Get live SLRN stock price $2.27, comprehensive Acelyrin, Inc. stock analysis, charts, news, and expert forecast. Real-time SLRN stock data and investment insights.

2.27
0.00%Today
SLRNAcelyrin, Inc. • NASDAQ Global Select • Healthcare
Market Cap
229.17M
Volume
4.06M
52W High
7.25
52W Low
1.84

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small prote...

Company Information

CEO
Mina Kim
Sector
Healthcare
Industry
Biotechnology
Employees
83

Contact Information

Address
4149 Liberty Canyon Road
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Acelyrin, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Acelyrin, Inc.
  • Investors should consider how Acelyrin, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

229.17M

P/E Ratio (TTM)

-0.84

Beta

1.09

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.